Esperion Therapeutics, Inc. ESPR 深 沪
等待开盘 02-04 09:30:00 美东时间
3.545
+0.045
+1.29%
华盛通- 最 高3.595
- 今 开3.53
- 成交量 68.44万股
- 最 低 3.46
- 昨 收 3.50
- 总市值 8.22亿
- 52周最高 4.175
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.6925
- 委 比 8.09%
- 总股本 2.32亿
- 历史最高 120.96
- 量 比 0.50
- 振 幅 3.86%
- 历史最低 0.6925
- 每 手 1
- 风险率 0.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多H.B. Fuller, Caledonia Mining And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
01-15 21:06
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics will present at the J.P. Morgan Healthcare Conference on January 14, 2025, at 2:15 PM PT/5:15 PM ET. The live webcast and replay will be available on their website. Esperion, a biopharmaceutical company, focuses on cardiometabolic and rare disease therapies using ACLY biology expertise. They offer LDL-C treatments and are expanding their pipeline with treatments for PSC and renal diseases, seeking partnerships for market acc...
01-05 13:00
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
Esperion welcomes ACC's inclusion of bempedoic acid as a first-line therapy for LDL-C lowering in PAD patients with diabetes, highlighting its proven benefits in reducing cardiovascular and limb risks. Key recommendations include reducing LDL-C by >50% and targeting <55 mg/dL, with bempedoic acid recommended alongside high-intensity statins. Data from the CLEAR Outcomes trial showed a 36% reduction in major adverse limb events with bempedoic acid...
2025-12-19 13:00
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion granted new employees stock options and RSUs under its 2017 Inducement Plan. John Harlow, the new Chief Commercial Officer, received 380,000 stock options and 424,536 RSUs. The options have an exercise price of $3.79 per share, vesting 25% after one year and the remaining 75% in quarterly installments. The RSUs vest similarly. Esperion focuses on developing medicines for cardiovascular disease, supported by clinical data and advancing it...
2025-12-09 21:30
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
Piper Sandler Initiates Coverage On Esperion Therapeutics with Overweight Rating, Announces Price Target of $9
Piper Sandler analyst David Amsellem initiates coverage on Esperion Therapeutics (NASDAQ:ESPR) with a Overweight rating and announces Price Target of $9.
2025-11-25 22:19
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Esperion announced that its Canadian partner, HLS Therapeutics, has received Health Canada approval to market NILEMDO and NEXLIZET for reducing LDL-Cholesterol in at-risk Canadians. This marks a significant milestone in Esperion's global strategy to expand access to its LDL-C lowering therapies. With cardiovascular disease affecting 2.6 million Canadians and being the second leading cause of death, the approval underscores the urgent need for eff...
2025-11-18 12:00
Esperion Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
Esperion Therapeutics shares are trading lower after the company reported worse...
2025-11-07 00:57
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion granted 23 new employees 77,650 restricted stock units (RSUs) on November 4, 2025, under its 2017 Inducement Equity Incentive Plan designed to attract new hires. Each RSU vests 25% one year after employment starts, with the remaining 75% vesting in 12 quarterly installments. Esperion, a biopharmaceutical company, focuses on developing innovative cardiovascular disease treatments, including ATP citrate lyase inhibitors, and builds on its ...
2025-11-06 21:30
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Snap Inc (NYSE:SNAP) rose sharply in pre-market trading after the com...
2025-11-06 19:32
